October 25, 2024 12:16 PM EDTUpdated 12:47 PM
Editor's note
Pharma
Manufacturing

Post-Hoc: No­vo’s obe­si­ty en­e­mies

Drew Armstrong

Executive Editor

This week, Roche joined Eli Lil­ly in com­ing out against a deal that would add sig­nif­i­cant new man­u­fac­tur­ing ca­pac­i­ty to No­vo Nordisk, to help it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Elu­ci­da On­col­o­gy, seek­ing foothold in AD­Cs, shut­ters due to 'lack of fund­ing'

Lyell Im­munophar­ma to ac­quire Imm­PACT Bio, cut top pro­grams

Tyra's stock dips as it gives first look in chal­lenge to J&J’s blad­der can­cer drug Balver­sa

Chi­nook alums re­unite fol­low­ing ex­it to No­var­tis; The first board ap­point­ment for Re­cur­sion’s Chris Gib­son

Rev­o­lu­tion Med­i­cines breaks ground in chal­leng­ing pan­cre­at­ic can­cer with two RAS drugs

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times